Production of high-complexity frameshift neoantigen peptide microarrays
- PMID: 35518269
- PMCID: PMC9056171
- DOI: 10.1039/d0ra05267a
Production of high-complexity frameshift neoantigen peptide microarrays
Abstract
Parallel measurement of large numbers of antigen-antibody interactions are increasingly enabled by peptide microarray technologies. Our group has developed an in situ synthesized peptide microarray of >400 000 frameshift neoantigens using mask-based photolithographic peptide synthesis, to profile patient specific neoantigen reactive antibodies in a single assay. The system produces 208 replicate mircoarrays per wafer and is capable of producing multiple wafers per synthetic lot to routinely synthesize over 300 million peptides simultaneously. In this report, we demonstrate the feasibility of the system for detecting peripheral-blood antibody binding to frameshift neoantigens across multiple synthetic lots.
This journal is © The Royal Society of Chemistry.
Conflict of interest statement
S. A. J. and L. S. hold patents and pending patents with respect to frameshift antigens and FSP arrays. S. A. J. is a founder of Calviri which is commercializing these diagnostic arrays. K. S. and J. R. B. are employees of Calviri. All authors have ownership interests in Calviri.
Figures
References
-
- Mattes D. S. Rentschler S. Foertsch T. C. Münch S. W. Loeffler F. F. Nesterov-Mueller A. Bräse S. Breitling F. Small Methods. 2018;2:1700205. doi: 10.1002/smtd.201700205. - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources
